MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03641cam a2200217 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
9781455727100 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
220107t2012 xxu||||| |||| 00| 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9781455727100 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9781437728644 |
| 041 ## - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| 100 ## - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Terkeltaub, Robert. |
| 245 #0 - TITLE STATEMENT |
|---|
| Title |
Gout and other crystal arthropathies |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Place of publication, distribution, etc. |
Philadelphia : |
| Name of publisher, distributor, etc. |
Elsevier/Saunders, |
| Date of publication, distribution, etc. |
2012 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
1 online resource (xiv, 357 pages):illustrations |
| 505 ## - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
I Foreword II Introduction 1 Pathology of Crystal Deposition Diseases 2 Synovial Fluid Crystal Analysis 3 Purine Metabolism in the Pathogenesis of Hyperuricemia, and Inborn Errors of Purine Metabolism Associated with Disease 4 Renal Basis of Hyperuricemia 5 Pathogenesis of Tophus Formation and Gouty Inflammation 6 Gout: Epidemiology and Risk Factors 7 Genetics of Gout 8 Diagnosis of Gout 9 Clinical Features of Gout 10 Treatment of Acute Gout 11 Diet, Alcohol, Obesity, and Hyperuricemia 12 Uricosuric Therapy of Hyperuricemia in Gout 13 Xanthine Oxidase Inhibitor Treatment of Hyperuricemia 14 Uricase Therapy of Gout 15 Prophylaxis of Attacks of Acute Gouty Arthritis 16 Overview of Gout Therapy Strategy and Targets and Management of Refractory Disease 17 Quality of Care in Gout 18 Health-Related Quality of Life and Outcome Measures in Gout 19 Asymptomatic Hyperuricemia: Cardiovascular and renal Implications 20 Pathogenesis and Molecular Genetics of Calcium Pyrophosphate Dihydrate Crystal Deposition Disease 21 Clinical Features, Diagnosis, and Treatment of CPPD Crystal Arthropathy 22 Basic Calcium Phosphate Crystal Arthropathy 23 Crystalline Disorders Associated with Renal Disease Including Oxalate Arthropathy 24 Plain Radiography and Advanced Imaging of Gout 25 Plain Radiography and Advanced Imaging of CPPD and Hydroxyapatite Deposition Diseases 26 Ultrasound in the Diagnosis of Crystal Deposition Disease 27 Developing the future of diagnosis and management of gout and other crystal deposition arthropathies. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
Gout and Other Crystal Arthropathies, by Dr. Robert Terkeltaub, presents the state-of-the-art, clinically-focused coverage you need to manage these increasingly prevalent diseases. Diagnose the full range of crystal arthropathies-including pseudogout, intercritical gout, hyperuricemia, and gouty arthritis-and treat your patients effectively with discussions of recently-approved drugs like Uloric and those currently under review, such as Kristexxa and Colcryst. With coverage of the latest therapies, preventions, and imaging studies, along with access to the fully searchable text online at www.expertconsult.com, this comprehensive resource is ideal for any physician who diagnoses, treats, and manages gout and crystal-induced arthropathies. Access the fully searchable contents online at www.expertconsult.com. Stay current on recent developments such as uricosuric therapy and inhibitor therapy; gout flare prophylaxis and colchicines; ultrasound in the diagnosis of crystal deposition diseases; imaging of gout, CPPD, and hydroxyapatitie deposition diseases; and uricase therapy of gout. Manage the full range of crystal arthropathies with 25 clinically-focused chapters on pseudogout, intercritical gout, hyperuricemia, gouty arthritis, and more. Treat your patients effectively using the latest information on drug treatments, from the recently-approved Uloric to Kristexx and Colcryst, which are still under review. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) |
|---|
| Topical term or geographic name as entry element |
Gout. |
| 9 (RLIN) |
6304 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) |
|---|
| Topical term or geographic name as entry element |
Chondrocalcinosis. |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
<a href="https://go.openathens.net/redirector/nhs?url=https://www.clinicalkey.com/dura/browse/bookChapter/3-s2.0-C20100656999">https://go.openathens.net/redirector/nhs?url=https://www.clinicalkey.com/dura/browse/bookChapter/3-s2.0-C20100656999</a> |